Stonepine Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Stonepine Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-216,307	Closed	-$2.38M	–	31
2017 Q2	$2.38M	Sell	216,307 -1,446,974	-87%	-$14.5M	1.28%	20
2017 Q1	$16.3M	Buy	1,663,281 +414,081	+33%	+$4.14M	9.19%	4
2016 Q4	$13.5M	Buy	+1,249,200	New	+$12.5M	8.04%	4
2016 Q3	–	Sell	-1,082,532	Closed	-$14.1M	–	24
2016 Q2	$14.1M	Sell	1,082,532 -966,106	-47%	-$12.7M	14.5%	1
2016 Q1	$22.5M	Buy	2,048,638 +873,064	+74%	+$7.76M	26.58%	1
2015 Q4	$10.8M	Buy	+1,175,574	New	+$9.84M	12.67%	3

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stonepine Capital Management's SCLN Position: Q3 2017 in Review

Stonepine Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 216,307 shares — an estimated $2.38M sold.

Stonepine Capital Management first reported a position in SCLN in Q4 2015 and held it in 6 quarters. The position peaked at $22.5M in Q1 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Stonepine Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Stonepine Capital Management sold 216,307 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $2.38M.
Stonepine Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 6 quarters.
Stonepine Capital Management's Sciclone Pharmaceuticals Inc position peaked at $22.5M in Q1 2016.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Stonepine Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.